Ian Knemeyer

1.6k total citations
9 papers, 500 citations indexed

About

Ian Knemeyer is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Ian Knemeyer has authored 9 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Pharmacology and 2 papers in Oncology. Recurrent topics in Ian Knemeyer's work include Pharmacogenetics and Drug Metabolism (3 papers), Analytical Chemistry and Chromatography (2 papers) and Computational Drug Discovery Methods (2 papers). Ian Knemeyer is often cited by papers focused on Pharmacogenetics and Drug Metabolism (3 papers), Analytical Chemistry and Chromatography (2 papers) and Computational Drug Discovery Methods (2 papers). Ian Knemeyer collaborates with scholars based in United States. Ian Knemeyer's co-authors include Mark Wirth, Stephen W.J. Wang, Jaime A. Yáñez, Kevin B. Alton, Yunsheng Hsieh, Walter A. Korfmacher, Jiwen Chen, Richard A. Morrison, Elaine K. Fukuda and M. Guillaume Wientjes and has published in prestigious journals such as Advanced Drug Delivery Reviews, Journal of Medicinal Chemistry and Toxicological Sciences.

In The Last Decade

Ian Knemeyer

9 papers receiving 488 citations

Peers

Countries citing papers authored by Ian Knemeyer

Since Specialization

Citations

This map shows the geographic impact of Ian Knemeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Knemeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Knemeyer more than expected).

Fields of papers citing papers by Ian Knemeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Knemeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Knemeyer. The network helps show where Ian Knemeyer may publish in the future.

Co-authorship network of co-authors of Ian Knemeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Knemeyer. A scholar is included among the top collaborators of Ian Knemeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Knemeyer. Ian Knemeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	In vivo bioluminescence imaging of labile iron in xenograft models and liver using FeAL-1, an iron-activatable form of D-luciferin 2023 ·Cell chemical biology ·(unknown), (unknown), (unknown), Cedric L. Hugelshofer, (unknown), Ian Knemeyer, Allegra T. Aron, Christopher J. Chang, John A. Flygare, Eric A. Collisson, Adam R. Renslo	7
2	Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold 2021 ·Bioorganic & Medicinal Chemistry Letters ·Wensheng Yu, Yongqi Deng, David L. Sloman, Derun Li, Kun Liu, Xavier Fradera, Charles A. Lesburg, Theodore A. Martinot, Amy C. Doty, Heidi M. Ferguson, J. Richard Miller, Ian Knemeyer, Karin M. Otte, Stella Vincent, Nunzio Sciammetta, David Jonathan Bennett, Yongxin Han	6
3	A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery 2020 ·Drug Metabolism and Disposition ·Michael J. Hafey, Robert Houle, Keith Q. Tanis, Ian Knemeyer, Jackie Shang, Qing Chen, Andreas R. Baudy, (unknown), Frank D. Sistare, Raymond Evers	14
4	Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline 2020 ·Toxicological Sciences ·(unknown), Alexei A. Podtelezhnikov, Keith Q. Tanis, Stephen Pacchione, (unknown), (unknown), Zhibin Wang, (unknown), Thomas G. Griffiths, (unknown), Qing Chen, Ian Knemeyer, Donald J. Marsh, Kaushik Mitra, José Antonio Lebrón, Frank D. Sistare	17
5	Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure–Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program 2016 ·Journal of Medicinal Chemistry ·Ting Zhang, Yong Liu, Xianshu Yang, Gary E. Martin, (unknown), Jackie Shang, Randal M. Bugianesi, Kenneth Ellsworth, Lisa M. Sonatore, (unknown), Edward C. Sherer, Susan E. Hill, Ian Knemeyer, Wayne M. Geissler, Peter J. Dandliker, Roy Helmy, Harold B. Wood	15
6	Intestinal lymphatic transport for drug delivery 2011 ·Advanced Drug Delivery Reviews ·Jaime A. Yáñez, Stephen W.J. Wang, Ian Knemeyer, Mark Wirth, Kevin B. Alton	208
7	Visualization of First-Pass Drug Metabolism of Terfenadine by MALDIImaging Mass Spectrometry 2008 ·Drug Metabolism Letters ·Yunsheng Hsieh, Jiwen Chen, Ian Knemeyer, (unknown), Walter A. Korfmacher	29
8	Matrix‐assisted laser desorption/ionization imaging mass spectrometry for direct measurement of clozapine in rat brain tissue 2006 ·Rapid Communications in Mass Spectrometry ·Yunsheng Hsieh, (unknown), Elaine K. Fukuda, Jiwen Chen, Ian Knemeyer, (unknown), Richard A. Morrison, Walter A. Korfmacher	151
9	Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment 1999 ·Cancer Chemotherapy and Pharmacology ·Ian Knemeyer, M. Guillaume Wientjes, Jessie L.‐S. Au	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact